Chemours (CC) Common Equity (2014 - 2026)

Chemours' Common Equity history runs 13 years deep, the most recent figure standing at $215.0 million for Q1 2026.

• On a quarterly basis, Common Equity fell 62.08% year-over-year to $215.0 million in Q1 2026; TTM through Mar 2026 was $215.0 million, a 62.08% decrease from a year earlier, with the FY2025 full-year figure at $250.0 million, down 56.29% from the prior year.
• Common Equity eased to $215.0 million in Q1 2026 per CC's latest filing, from $250.0 million in the prior quarter.
• Across five years, Common Equity topped out at $1.8 billion in Q2 2024 and bottomed at $215.0 million in Q1 2026.
• The 5-year median for Common Equity is $810.0 million (2023), against an average of $926.9 million.
• Across the five-year window, Common Equity jumped 133.51% in 2024 and plunged 87.36% in 2025, its largest moves.
• Year by year, Common Equity stood at $1.1 billion in 2022, then plunged by 34.81% to $721.0 million in 2023, then retreated by 20.67% to $572.0 million in 2024, then tumbled by 56.29% to $250.0 million in 2025, then slipped by 14.0% to $215.0 million in 2026.
• Per Business Quant, the three latest CC Common Equity figures stand at $215.0 million (Q1 2026), $250.0 million (Q4 2025), and $276.0 million (Q3 2025).